| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biosimilar Pharmaceuticals | 27 | 2023 | 28 | 13.090 |
Why?
|
| Arthritis, Rheumatoid | 53 | 2025 | 322 | 11.590 |
Why?
|
| Antirheumatic Agents | 42 | 2025 | 214 | 9.120 |
Why?
|
| Rheumatic Diseases | 15 | 2025 | 38 | 4.810 |
Why?
|
| Rheumatology | 17 | 2025 | 66 | 4.770 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 17 | 2016 | 22 | 4.460 |
Why?
|
| Contrast Media | 16 | 2016 | 407 | 3.330 |
Why?
|
| Gadolinium | 14 | 2016 | 103 | 3.200 |
Why?
|
| Spondylarthritis | 11 | 2024 | 40 | 2.840 |
Why?
|
| Arthritis, Psoriatic | 9 | 2025 | 33 | 2.790 |
Why?
|
| Spondylitis, Ankylosing | 9 | 2024 | 24 | 2.640 |
Why?
|
| Antibodies, Monoclonal | 20 | 2025 | 836 | 2.510 |
Why?
|
| Infliximab | 12 | 2022 | 49 | 2.410 |
Why?
|
| Methotrexate | 15 | 2021 | 76 | 2.160 |
Why?
|
| Adalimumab | 9 | 2023 | 30 | 1.520 |
Why?
|
| Humans | 145 | 2025 | 59106 | 1.520 |
Why?
|
| Kidney Failure, Chronic | 12 | 2010 | 206 | 1.380 |
Why?
|
| Drug Approval | 6 | 2020 | 25 | 1.290 |
Why?
|
| Double-Blind Method | 20 | 2022 | 714 | 1.240 |
Why?
|
| Skin Diseases | 6 | 2016 | 76 | 1.080 |
Why?
|
| United States Food and Drug Administration | 3 | 2024 | 86 | 1.080 |
Why?
|
| Joints | 4 | 2017 | 32 | 1.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2025 | 584 | 1.060 |
Why?
|
| Skin | 10 | 2016 | 357 | 1.020 |
Why?
|
| Gadolinium DTPA | 4 | 2016 | 84 | 0.960 |
Why?
|
| Treatment Outcome | 26 | 2025 | 5227 | 0.920 |
Why?
|
| Fibrosis | 8 | 2013 | 153 | 0.890 |
Why?
|
| Therapeutic Equivalency | 5 | 2022 | 16 | 0.810 |
Why?
|
| Crohn Disease | 1 | 2023 | 105 | 0.800 |
Why?
|
| Middle Aged | 47 | 2024 | 16240 | 0.790 |
Why?
|
| Biological Therapy | 4 | 2019 | 16 | 0.780 |
Why?
|
| Male | 57 | 2024 | 27623 | 0.770 |
Why?
|
| Arthritis | 2 | 2020 | 49 | 0.760 |
Why?
|
| Vasculitis | 4 | 2024 | 50 | 0.740 |
Why?
|
| Severity of Illness Index | 16 | 2017 | 1476 | 0.740 |
Why?
|
| Female | 60 | 2024 | 30613 | 0.730 |
Why?
|
| Azetidines | 1 | 2020 | 7 | 0.710 |
Why?
|
| Bone and Bones | 3 | 2016 | 137 | 0.700 |
Why?
|
| Adult | 40 | 2024 | 15615 | 0.700 |
Why?
|
| Hematologic Agents | 1 | 2020 | 3 | 0.690 |
Why?
|
| Filgrastim | 1 | 2020 | 6 | 0.690 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 20 | 0.640 |
Why?
|
| Patient Care Management | 1 | 2019 | 29 | 0.640 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2019 | 2055 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 700 | 0.630 |
Why?
|
| Kidney Diseases | 3 | 2011 | 166 | 0.610 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 201 | 0.600 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 143 | 0.600 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 305 | 0.590 |
Why?
|
| Spondylarthropathies | 2 | 2019 | 4 | 0.590 |
Why?
|
| Amyloidosis | 9 | 2008 | 62 | 0.580 |
Why?
|
| United States | 11 | 2024 | 7370 | 0.560 |
Why?
|
| Organometallic Compounds | 3 | 2016 | 63 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2014 | 113 | 0.550 |
Why?
|
| Acquired Hyperostosis Syndrome | 1 | 2016 | 1 | 0.550 |
Why?
|
| Biological Products | 3 | 2024 | 90 | 0.540 |
Why?
|
| Osteoarthritis | 3 | 2024 | 131 | 0.530 |
Why?
|
| C-Reactive Protein | 5 | 2019 | 159 | 0.520 |
Why?
|
| Acute-Phase Proteins | 2 | 2014 | 34 | 0.520 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 518 | 0.520 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2025 | 219 | 0.510 |
Why?
|
| Immunologic Factors | 4 | 2015 | 102 | 0.510 |
Why?
|
| Exercise | 2 | 2020 | 883 | 0.510 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 2509 | 0.500 |
Why?
|
| Molecular Targeted Therapy | 4 | 2025 | 120 | 0.490 |
Why?
|
| Aged | 28 | 2019 | 13348 | 0.490 |
Why?
|
| beta 2-Microglobulin | 10 | 2001 | 48 | 0.470 |
Why?
|
| Macrophages | 4 | 2014 | 1000 | 0.470 |
Why?
|
| Meglumine | 2 | 2016 | 18 | 0.460 |
Why?
|
| Peritoneum | 1 | 2014 | 26 | 0.460 |
Why?
|
| Hypophosphatemia | 1 | 2014 | 6 | 0.450 |
Why?
|
| Peritonitis | 1 | 2014 | 35 | 0.450 |
Why?
|
| Cryoglobulinemia | 2 | 2005 | 3 | 0.450 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 7 | 0.450 |
Why?
|
| Immunoglobulin G | 4 | 2018 | 444 | 0.440 |
Why?
|
| Polychondritis, Relapsing | 1 | 2013 | 3 | 0.430 |
Why?
|
| Remission Induction | 8 | 2019 | 137 | 0.430 |
Why?
|
| Gastrointestinal Diseases | 2 | 2013 | 69 | 0.420 |
Why?
|
| Rare Diseases | 1 | 2013 | 38 | 0.410 |
Why?
|
| Injections, Subcutaneous | 6 | 2021 | 69 | 0.410 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 257 | 0.410 |
Why?
|
| Risk Factors | 11 | 2018 | 4948 | 0.400 |
Why?
|
| Global Health | 1 | 2013 | 167 | 0.400 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 75 | 0.390 |
Why?
|
| Piperazines | 2 | 2011 | 74 | 0.380 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 65 | 0.380 |
Why?
|
| Drug Therapy, Combination | 8 | 2021 | 452 | 0.380 |
Why?
|
| Pyrimidines | 2 | 2011 | 129 | 0.370 |
Why?
|
| Drugs, Generic | 1 | 2011 | 16 | 0.370 |
Why?
|
| Neoplasms | 3 | 2022 | 1239 | 0.370 |
Why?
|
| Kidney | 4 | 2016 | 412 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 171 | 0.360 |
Why?
|
| Glycation End Products, Advanced | 5 | 2003 | 18 | 0.360 |
Why?
|
| Bursitis | 1 | 2010 | 13 | 0.350 |
Why?
|
| Area Under Curve | 3 | 2021 | 141 | 0.350 |
Why?
|
| Inflammasomes | 1 | 2014 | 324 | 0.350 |
Why?
|
| Renal Dialysis | 6 | 2000 | 189 | 0.350 |
Why?
|
| Diabetes Complications | 1 | 2010 | 99 | 0.340 |
Why?
|
| Societies, Medical | 5 | 2024 | 332 | 0.340 |
Why?
|
| Comorbidity | 5 | 2013 | 1077 | 0.330 |
Why?
|
| Autopsy | 1 | 2009 | 50 | 0.330 |
Why?
|
| Carrier Proteins | 1 | 2014 | 696 | 0.330 |
Why?
|
| Cost Savings | 2 | 2020 | 52 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 675 | 0.320 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2025 | 158 | 0.320 |
Why?
|
| Software | 2 | 2009 | 367 | 0.310 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 60 | 0.310 |
Why?
|
| Terminology as Topic | 6 | 2016 | 129 | 0.310 |
Why?
|
| Cohort Studies | 5 | 2023 | 2367 | 0.300 |
Why?
|
| Diagnosis, Differential | 7 | 2016 | 930 | 0.300 |
Why?
|
| Teriparatide | 2 | 2018 | 6 | 0.290 |
Why?
|
| Pulmonary Fibrosis | 1 | 2008 | 79 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 806 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2022 | 1514 | 0.280 |
Why?
|
| Quality of Life | 6 | 2024 | 1134 | 0.280 |
Why?
|
| Disease Progression | 6 | 2017 | 1120 | 0.280 |
Why?
|
| Back Pain | 3 | 2022 | 48 | 0.270 |
Why?
|
| Radiography | 4 | 2017 | 515 | 0.270 |
Why?
|
| Prevalence | 5 | 2013 | 1250 | 0.260 |
Why?
|
| Qualitative Research | 5 | 2022 | 618 | 0.260 |
Why?
|
| Temporal Arteries | 1 | 2006 | 4 | 0.260 |
Why?
|
| Receptors, Immunologic | 5 | 2003 | 176 | 0.260 |
Why?
|
| Giant Cell Arteritis | 1 | 2006 | 5 | 0.260 |
Why?
|
| Databases, Factual | 4 | 2024 | 805 | 0.260 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 788 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 441 | 0.260 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2005 | 5 | 0.250 |
Why?
|
| Attitude of Health Personnel | 2 | 2009 | 548 | 0.250 |
Why?
|
| Antibodies, Antinuclear | 2 | 2018 | 36 | 0.250 |
Why?
|
| Interleukin-1 | 3 | 2004 | 156 | 0.240 |
Why?
|
| Monocytes | 4 | 2001 | 342 | 0.230 |
Why?
|
| Internationality | 2 | 2015 | 43 | 0.230 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 66 | 0.230 |
Why?
|
| Drug Industry | 3 | 2018 | 39 | 0.230 |
Why?
|
| Biomedical Research | 2 | 2017 | 248 | 0.220 |
Why?
|
| Hospitals, General | 1 | 2023 | 13 | 0.220 |
Why?
|
| Rituximab | 3 | 2017 | 80 | 0.220 |
Why?
|
| Massachusetts | 3 | 2023 | 2004 | 0.210 |
Why?
|
| Physicians, Primary Care | 2 | 2021 | 72 | 0.210 |
Why?
|
| Drug Costs | 2 | 2020 | 54 | 0.210 |
Why?
|
| Gout | 2 | 2016 | 48 | 0.200 |
Why?
|
| Inflammation | 2 | 2021 | 1093 | 0.200 |
Why?
|
| Ultrasonography | 2 | 2016 | 457 | 0.200 |
Why?
|
| Psoriasis | 1 | 2022 | 50 | 0.190 |
Why?
|
| Europe | 5 | 2015 | 184 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 38 | 0.190 |
Why?
|
| Dopamine | 1 | 2022 | 102 | 0.190 |
Why?
|
| Patient Care Planning | 2 | 2019 | 84 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 105 | 0.190 |
Why?
|
| Drug Substitution | 3 | 2025 | 40 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 723 | 0.180 |
Why?
|
| Republic of Korea | 1 | 2021 | 29 | 0.180 |
Why?
|
| Depression, Postpartum | 1 | 2023 | 129 | 0.180 |
Why?
|
| Hyperpigmentation | 2 | 2012 | 6 | 0.180 |
Why?
|
| Janus Kinase 1 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Purines | 1 | 2020 | 38 | 0.180 |
Why?
|
| Philadelphia | 1 | 2020 | 19 | 0.170 |
Why?
|
| Medicare Part B | 1 | 2020 | 10 | 0.170 |
Why?
|
| Fatal Outcome | 3 | 2009 | 114 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2020 | 64 | 0.170 |
Why?
|
| Attitude | 1 | 2020 | 96 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 17 | 0.170 |
Why?
|
| Synovial Fluid | 2 | 1991 | 29 | 0.170 |
Why?
|
| European Union | 1 | 2020 | 11 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2002 | 143 | 0.170 |
Why?
|
| Reimbursement Mechanisms | 1 | 2020 | 40 | 0.170 |
Why?
|
| Iatrogenic Disease | 1 | 2000 | 55 | 0.170 |
Why?
|
| Personality Disorders | 1 | 1999 | 19 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6030 | 0.170 |
Why?
|
| Disability Evaluation | 2 | 2012 | 199 | 0.170 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 165 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 55 | 0.170 |
Why?
|
| Benzamides | 2 | 2011 | 63 | 0.170 |
Why?
|
| Gastroenterology | 1 | 2020 | 35 | 0.160 |
Why?
|
| Sulfonamides | 1 | 2020 | 120 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 57 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2019 | 1898 | 0.160 |
Why?
|
| Patient Acuity | 1 | 2019 | 19 | 0.160 |
Why?
|
| Sacroiliitis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Patient Participation | 2 | 2019 | 216 | 0.160 |
Why?
|
| Biopsy | 4 | 2011 | 407 | 0.160 |
Why?
|
| Certolizumab Pegol | 1 | 2019 | 2 | 0.160 |
Why?
|
| Lyme Disease | 2 | 1993 | 104 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 1558 | 0.160 |
Why?
|
| Animals | 11 | 2022 | 19589 | 0.160 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 440 | 0.160 |
Why?
|
| Pain | 4 | 2024 | 393 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2025 | 3052 | 0.160 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 165 | 0.160 |
Why?
|
| Data Mining | 1 | 2019 | 34 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 297 | 0.150 |
Why?
|
| Consensus | 2 | 2017 | 193 | 0.150 |
Why?
|
| Glucocorticoids | 2 | 2013 | 179 | 0.150 |
Why?
|
| Guideline Adherence | 3 | 2024 | 288 | 0.150 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2018 | 6 | 0.150 |
Why?
|
| Aged, 80 and over | 6 | 2011 | 5101 | 0.150 |
Why?
|
| Motivation | 1 | 2020 | 273 | 0.140 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 19 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1048 | 0.140 |
Why?
|
| Time Factors | 9 | 2025 | 3586 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 203 | 0.140 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 53 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 99 | 0.140 |
Why?
|
| Bipolar Disorder | 1 | 1999 | 242 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2017 | 44 | 0.140 |
Why?
|
| Delayed Diagnosis | 3 | 2022 | 42 | 0.140 |
Why?
|
| Review Literature as Topic | 2 | 2016 | 33 | 0.140 |
Why?
|
| Snail Family Transcription Factors | 1 | 2016 | 28 | 0.140 |
Why?
|
| Biomarkers | 4 | 2024 | 1304 | 0.140 |
Why?
|
| Social Media | 1 | 2019 | 113 | 0.140 |
Why?
|
| Bone Density | 1 | 2017 | 129 | 0.130 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 120 | 0.130 |
Why?
|
| Alcoholism | 1 | 1999 | 308 | 0.130 |
Why?
|
| Physicians | 1 | 2021 | 423 | 0.130 |
Why?
|
| Uric Acid | 1 | 2016 | 45 | 0.130 |
Why?
|
| Young Adult | 3 | 2024 | 4250 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 44 | 0.130 |
Why?
|
| Hand Bones | 1 | 2016 | 1 | 0.130 |
Why?
|
| Heterocyclic Compounds | 1 | 2016 | 12 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 137 | 0.130 |
Why?
|
| Hedgehog Proteins | 1 | 2016 | 109 | 0.130 |
Why?
|
| Mass Screening | 1 | 2021 | 643 | 0.130 |
Why?
|
| Hand Joints | 1 | 2016 | 21 | 0.120 |
Why?
|
| International Agencies | 1 | 2015 | 7 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 1022 | 0.120 |
Why?
|
| Biological Availability | 1 | 2016 | 195 | 0.120 |
Why?
|
| China | 2 | 2015 | 134 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2015 | 115 | 0.120 |
Why?
|
| Bone Resorption | 2 | 2016 | 41 | 0.120 |
Why?
|
| Creatinine | 3 | 2011 | 127 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2015 | 108 | 0.110 |
Why?
|
| Health Status | 2 | 2021 | 424 | 0.110 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2014 | 60 | 0.110 |
Why?
|
| Fibronectins | 2 | 1991 | 43 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 168 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 146 | 0.110 |
Why?
|
| Caveolin 1 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ear Cartilage | 1 | 2013 | 7 | 0.110 |
Why?
|
| Self Report | 1 | 2015 | 359 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 53 | 0.100 |
Why?
|
| Scleroderma, Diffuse | 1 | 2012 | 2 | 0.100 |
Why?
|
| Raynaud Disease | 1 | 2012 | 4 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 251 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2013 | 102 | 0.100 |
Why?
|
| Contracture | 1 | 2012 | 8 | 0.100 |
Why?
|
| Dexamethasone | 1 | 1994 | 201 | 0.100 |
Why?
|
| Imatinib Mesylate | 2 | 2011 | 33 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2013 | 132 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 1994 | 187 | 0.100 |
Why?
|
| Canada | 1 | 2012 | 145 | 0.100 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2014 | 250 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 521 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2013 | 169 | 0.100 |
Why?
|
| Congresses as Topic | 2 | 2025 | 71 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 330 | 0.100 |
Why?
|
| Shoulder | 2 | 2010 | 24 | 0.100 |
Why?
|
| North America | 4 | 2015 | 106 | 0.100 |
Why?
|
| Arthrography | 1 | 2011 | 7 | 0.090 |
Why?
|
| Opsonin Proteins | 1 | 1991 | 31 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2009 | 270 | 0.090 |
Why?
|
| Dermis | 1 | 2011 | 16 | 0.090 |
Why?
|
| Shoulder Impingement Syndrome | 1 | 2010 | 2 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 365 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 438 | 0.090 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2011 | 47 | 0.090 |
Why?
|
| Adolescent | 4 | 2016 | 5816 | 0.090 |
Why?
|
| Muscular Diseases | 2 | 2006 | 46 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 2368 | 0.090 |
Why?
|
| Range of Motion, Articular | 1 | 2010 | 85 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 120 | 0.090 |
Why?
|
| International Cooperation | 4 | 2010 | 84 | 0.090 |
Why?
|
| Registries | 1 | 2014 | 795 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2022 | 156 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2011 | 324 | 0.080 |
Why?
|
| Edema | 2 | 2009 | 42 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2011 | 268 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2013 | 913 | 0.080 |
Why?
|
| Serum Amyloid A Protein | 1 | 2009 | 7 | 0.080 |
Why?
|
| E-Selectin | 1 | 2009 | 18 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 140 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2009 | 68 | 0.080 |
Why?
|
| Medical Informatics Applications | 1 | 2009 | 14 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1985 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2044 | 0.080 |
Why?
|
| Pregnancy | 3 | 2023 | 2202 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2009 | 71 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 59 | 0.080 |
Why?
|
| Drug Eruptions | 1 | 2008 | 14 | 0.080 |
Why?
|
| Cause of Death | 1 | 2009 | 207 | 0.080 |
Why?
|
| Eosinophilia | 1 | 1988 | 29 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 428 | 0.080 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2008 | 5 | 0.080 |
Why?
|
| Chondrocalcinosis | 1 | 2008 | 3 | 0.080 |
Why?
|
| Uremia | 1 | 2008 | 9 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 411 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 26 | 0.070 |
Why?
|
| Joint Diseases | 1 | 2008 | 18 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 3 | 2003 | 19 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 670 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 629 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2011 | 392 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2008 | 94 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 170 | 0.070 |
Why?
|
| Acanthamoeba | 1 | 2006 | 1 | 0.070 |
Why?
|
| Amebiasis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3219 | 0.070 |
Why?
|
| Shock, Septic | 1 | 2008 | 86 | 0.070 |
Why?
|
| Granuloma | 1 | 2006 | 41 | 0.070 |
Why?
|
| Pneumonia | 1 | 2009 | 279 | 0.070 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2006 | 14 | 0.070 |
Why?
|
| Encephalitis | 1 | 2006 | 33 | 0.070 |
Why?
|
| Acute-Phase Reaction | 3 | 2010 | 18 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 635 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2013 | 717 | 0.070 |
Why?
|
| Synovitis | 3 | 2010 | 30 | 0.060 |
Why?
|
| Mice | 3 | 2022 | 10247 | 0.060 |
Why?
|
| Pharyngitis | 1 | 2006 | 12 | 0.060 |
Why?
|
| Myocardium | 1 | 2008 | 264 | 0.060 |
Why?
|
| Early Diagnosis | 3 | 2010 | 91 | 0.060 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2005 | 1 | 0.060 |
Why?
|
| Knee Joint | 1 | 2008 | 285 | 0.060 |
Why?
|
| Autoantibodies | 2 | 2018 | 171 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 2330 | 0.060 |
Why?
|
| Exanthema | 1 | 2005 | 26 | 0.060 |
Why?
|
| Prednisone | 1 | 2005 | 85 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1223 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 6 | 0.060 |
Why?
|
| Fatigue | 1 | 2006 | 103 | 0.060 |
Why?
|
| Dyspnea | 1 | 2006 | 116 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2025 | 40 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 130 | 0.060 |
Why?
|
| Interleukin-23 | 1 | 2024 | 19 | 0.060 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2004 | 66 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2025 | 102 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 206 | 0.060 |
Why?
|
| Anorexia Nervosa | 1 | 1983 | 16 | 0.050 |
Why?
|
| Research Design | 2 | 2017 | 555 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 322 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 98 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 220 | 0.050 |
Why?
|
| Collagen | 3 | 1998 | 115 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 2014 | 64 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2002 | 12 | 0.050 |
Why?
|
| Glucans | 2 | 1994 | 63 | 0.050 |
Why?
|
| Ion Channels | 1 | 2022 | 88 | 0.050 |
Why?
|
| Trisomy | 1 | 2002 | 19 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 98 | 0.050 |
Why?
|
| Etanercept | 2 | 2013 | 32 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2013 | 62 | 0.050 |
Why?
|
| Sports Medicine | 1 | 2021 | 22 | 0.050 |
Why?
|
| Cytokines | 2 | 2016 | 904 | 0.050 |
Why?
|
| Syringes | 1 | 2021 | 10 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 934 | 0.050 |
Why?
|
| General Practitioners | 1 | 2021 | 14 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1189 | 0.050 |
Why?
|
| Phagocytosis | 2 | 1994 | 249 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 714 | 0.040 |
Why?
|
| Triazoles | 1 | 2021 | 51 | 0.040 |
Why?
|
| Psychometrics | 1 | 2022 | 362 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 98 | 0.040 |
Why?
|
| Hypertension | 1 | 2005 | 567 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 129 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1999 | 379 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 1485 | 0.040 |
Why?
|
| Guanidines | 1 | 1998 | 14 | 0.040 |
Why?
|
| Cognition | 1 | 2022 | 454 | 0.040 |
Why?
|
| Denmark | 1 | 2018 | 16 | 0.040 |
Why?
|
| Sweden | 1 | 2018 | 42 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2021 | 341 | 0.040 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 15 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 114 | 0.040 |
Why?
|
| Infant | 1 | 2022 | 1482 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 39 | 0.040 |
Why?
|
| Ulna | 1 | 2017 | 4 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 50 | 0.040 |
Why?
|
| Radius | 1 | 2017 | 13 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2017 | 9 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 55 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 65 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 94 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 20 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 710 | 0.030 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2016 | 1 | 0.030 |
Why?
|
| Patched Receptors | 1 | 2016 | 10 | 0.030 |
Why?
|
| Keloid | 1 | 2016 | 3 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 26 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 846 | 0.030 |
Why?
|
| Health Priorities | 1 | 2016 | 23 | 0.030 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1996 | 28 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 85 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 103 | 0.030 |
Why?
|
| Cicatrix | 1 | 2016 | 58 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1998 | 376 | 0.030 |
Why?
|
| Medicaid | 1 | 2019 | 334 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2001 | 2088 | 0.030 |
Why?
|
| Pharmacovigilance | 1 | 2016 | 13 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 348 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 18 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 736 | 0.030 |
Why?
|
| ROC Curve | 1 | 1996 | 266 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 153 | 0.030 |
Why?
|
| Apoptosis | 1 | 2001 | 1032 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2016 | 140 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2021 | 643 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 18 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 598 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 187 | 0.030 |
Why?
|
| Algorithms | 2 | 2010 | 974 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 185 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 1993 | 730 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 1998 | 845 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 299 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 1996 | 289 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 1991 | 39 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 239 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1994 | 75 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 587 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 1090 | 0.030 |
Why?
|
| Codon | 1 | 2013 | 48 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2013 | 118 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 520 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 452 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 283 | 0.030 |
Why?
|
| Introns | 1 | 2013 | 104 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 1992 | 24 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 402 | 0.020 |
Why?
|
| Bone Diseases | 1 | 1992 | 21 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 130 | 0.020 |
Why?
|
| Bacterial Vaccines | 1 | 1993 | 86 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 652 | 0.020 |
Why?
|
| Anemia | 1 | 2013 | 119 | 0.020 |
Why?
|
| Kinetics | 1 | 1994 | 750 | 0.020 |
Why?
|
| Cell Line | 2 | 1998 | 1967 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1991 | 75 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1991 | 48 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1991 | 183 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 127 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 896 | 0.020 |
Why?
|
| Clinical Chemistry Tests | 1 | 2010 | 6 | 0.020 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2010 | 12 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2010 | 47 | 0.020 |
Why?
|
| Epitopes | 1 | 1991 | 285 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1991 | 582 | 0.020 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1989 | 1 | 0.020 |
Why?
|
| Receptors, Very Late Antigen | 1 | 1989 | 1 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1989 | 105 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 84 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 673 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 1134 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 132 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2010 | 195 | 0.020 |
Why?
|
| Antibodies | 2 | 2001 | 179 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 141 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 178 | 0.020 |
Why?
|
| Borrelia | 1 | 1988 | 25 | 0.020 |
Why?
|
| Calcium Oxalate | 1 | 2008 | 12 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2008 | 25 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1988 | 216 | 0.020 |
Why?
|
| Crystallization | 1 | 2008 | 97 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 458 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1989 | 281 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1226 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 1988 | 186 | 0.020 |
Why?
|
| Glycosylation | 2 | 1998 | 129 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 21 | 0.020 |
Why?
|
| Arm | 1 | 2006 | 42 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1989 | 743 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2006 | 29 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Seizures | 1 | 2006 | 113 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1989 | 620 | 0.020 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 1 | 2004 | 1 | 0.010 |
Why?
|
| Acanthocytes | 1 | 1983 | 1 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1983 | 8 | 0.010 |
Why?
|
| Leukopenia | 1 | 1983 | 16 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1998 | 468 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1983 | 97 | 0.010 |
Why?
|
| Child | 1 | 1993 | 4168 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1983 | 42 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1983 | 58 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1983 | 157 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1983 | 114 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1983 | 118 | 0.010 |
Why?
|
| Attitude to Health | 1 | 1983 | 279 | 0.010 |
Why?
|
| Superoxides | 1 | 2001 | 69 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2001 | 39 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2001 | 49 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 44 | 0.010 |
Why?
|
| fas Receptor | 1 | 2001 | 55 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2001 | 191 | 0.010 |
Why?
|
| Lysosomes | 1 | 2001 | 156 | 0.010 |
Why?
|
| Propionibacterium acnes | 1 | 1979 | 6 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 442 | 0.010 |
Why?
|
| Procollagen | 1 | 1998 | 10 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1979 | 144 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 1998 | 51 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 48 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1998 | 90 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1998 | 187 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 660 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 444 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1998 | 224 | 0.010 |
Why?
|
| Glucose | 1 | 1998 | 445 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1979 | 982 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1463 | 0.010 |
Why?
|
| Hip | 1 | 1992 | 7 | 0.010 |
Why?
|
| Wrist | 1 | 1992 | 32 | 0.010 |
Why?
|
| Spine | 1 | 1992 | 42 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 1989 | 28 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1989 | 62 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1989 | 137 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1989 | 132 | 0.000 |
Why?
|
| Ascitic Fluid | 1 | 1979 | 12 | 0.000 |
Why?
|
| Leukemia, Experimental | 1 | 1979 | 19 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1979 | 83 | 0.000 |
Why?
|
| Cell Separation | 1 | 1979 | 145 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1979 | 207 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1979 | 169 | 0.000 |
Why?
|
| Spleen | 1 | 1979 | 479 | 0.000 |
Why?
|